LENTIVIRAL VECTORS MARKET ANALYSIS

Market News

In July 2022, Oxford Biomedica, a gene and cell therapy company specialising in the development of gene-based medicines, announced that it has signed a new Licence and Supply Agreement (LSA) with an undisclosed U.S.-based private biotechnology company advancing a new generation of adoptive cell therapies. The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica’s LentiVector platform for its application in their lead (chimeric antigen receptors-therapy) CAR-T programme, and puts in place a three-year Clinical Supply Agreement. Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of products sold that utilise the Company’s LentiVector platform.

In November 2022, ReiThera srl, a biotech company dedicated to the development of new technologies, (good manufacturing practices) GMP production, and the clinical translation of genetic vaccines and products for advanced therapies, announced that it has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area at its pharmaceutical facility at the Castel Romano Technopole, for the large-scale production of viral vectors for vaccines and gene therapy.

In May 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) granted conditional marketing authorization of CARVYKTI for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.

Global Lentiviral Vectors Market- Key Developments

On February 07 2023, Genenta Science, a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics, a global Contract Development and Manufacturing Organization to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing and quality/regulatory services, supported by scientists with 30 years of knowledge and experience.